Advanced Oncotherapy PLC Director/PDMR Shareholding (4971W)

TIDMAVO

RNS Number : 4971W

Advanced Oncotherapy PLC

18 August 2020

18 August 2020

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

Director/PDMR Shareholding

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that Dr. Michael Sinclair, Executive Chairman, has purchased a total of 145,000 ordinary shares of 25p each in the Company ("Ordinary Shares") at an average price of 32.18 pence per share.

Following these purchases, Dr Sinclair has a total beneficial interest in 8,280,604 Ordinary Shares, equivalent to 2.70 per cent. of the Company's issued share capital.

Further details and the information required in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014 are set out at the end of this announcement.

 
  Advanced Oncotherapy plc                                        www.avoplc.com 
  Dr. Michael Sinclair, Executive                      Tel: [phone] 
   Chairman 
  Nicolas Serandour, CEO 
 
  Allenby Capital Limited (Nomad 
   & Broker) 
  Nick Athanas / Liz Kirchner (Corporate               Tel: [phone] 
   Finance) 
   Amrit Nahal / Matt Butlin (Sales 
   & Broking) 
 
  FTI Consulting (Financial PR             [e-mail] 
   & IR) 
  Simon Conway / Rob Winder                            Tel: [phone] 
 

Notes for Editors

About Advanced Oncotherapy Plc www.avoplc.com

Advanced Oncotherapy, a UK headquartered company with offices in London, Geneva, The Netherlands and in the USA, is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM," based in Geneva, focuses on the development of a proprietary proton accelerator called, Linac Image Guided Hadron Technology (LIGHT). LIGHT's compact configuration delivers proton beams in a way that facilitates greater precision and electronic control.

Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with innovative technology as well as expected lower treatment-related side effects.

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

 
 1    Details of the person discharging managerial responsibilities 
 a)   Name                        Michael Sinclair 
     --------------------------  --------------------------------------- 
 2    Reason for the notification 
     ------------------------------------------------------------------- 
 a)   Position/status             Executive Chairman 
     --------------------------  --------------------------------------- 
 b)   Initial notification        Initial notification 
       /Amendment 
     --------------------------  --------------------------------------- 
 3    Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     ------------------------------------------------------------------- 
 a)   Name                        Advanced Oncotherapy plc 
     --------------------------  --------------------------------------- 
 b)   LEI                         213800LUDHZOG3YT6C82 
     --------------------------  --------------------------------------- 
 4    Details of the transaction(s): section to be repeated for 
       (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions have 
       been conducted 
     ------------------------------------------------------------------- 
 a)   Description of the          Ordinary shares of 25p each in 
       financial instrument,       Advanced Oncotherapy plc 
       type of instrument          Identification code (ISIN) for 
       Identification code         Advanced Oncotherapy plc ordinary 
                                   shares: GB00BD6SX109 
     --------------------------  --------------------------------------- 
 b)   Nature of the transaction   Purchase of shares 
     --------------------------  --------------------------------------- 
 c)   Price(s) and volume(s)        Date         Volume   Average price 
                                                            (pence) 
                                     17 August 
                                      2020        65,000   29.97 
                                                 -------  -------------- 
                                     18 August 
                                      2020        80,000   33.97 
                                                 -------  -------------- 
     --------------------------  --------------------------------------- 
 d)   Aggregated information 
       - Aggregated volume          145,000 Ordinary Shares 
       - Price                      Average price of 32.18 pence 
                                    per Ordinary Share 
     --------------------------  --------------------------------------- 
 e)   Date of the transaction     See 4 c) above 
     --------------------------  --------------------------------------- 
 f)   Place of the transaction    London Stock Exchange 
     --------------------------  --------------------------------------- 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

DSHBUGDIIDBDGGI

(END) Dow Jones Newswires

August 18, 2020 11:30 ET (15:30 GMT)